– SWITZERLAND, Pfäffikon –  Numab Therapeutics AG today announced the appointment of former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors, effective October 1st.

“We are delighted to welcome Daniel Vasella to our Board of Directors. At our current stage of development, we expect to greatly benefit from Daniel’s vast experience. As we advance our proprietary pipeline programs and expand our roster of pharma collaborations, his strategic advice will be invaluable, and we look forward to working closely with him to bring Numab to the next stage,” said Dr. David Urech, CEO of Numab.

About Daniel Vasella

Dr. Daniel Vasella served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis AG from 1996 to January 2010. From 1992 to 1996, Dr. Vasella held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President and Head of Worldwide Development and Head of Corporate Marketing at Sandoz Pharma Ltd. He also served at Sandoz Pharmaceuticals Corporation from 1988 to 1992. Dr. Vasella is currently working as a coach to senior executives. He is also a director of PepsiCo and American Express Company and is a member of several non-profit organizations.

About Numab Therapeutics

Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology and has partnerships with Eisai, CStone Pharmaceuticals, Ono Pharmaceutical, Kaken Pharmaceutical, and Tillotts Pharma. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile.

For more information: http://www.numab.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.